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Summary
Alzheimer’s disease (AD) is the leading cause of dementia, with metabolic dysfunction
seen years before the emergence of clinical symptoms. Increasing evidence suggests
a role for primary and secondary bile acids, the end-product of cholesterol metabolism,
influencing pathophysiology in AD. In this study, we analyzed transcriptomes from 2114
post-mortem brain samples from three independent cohorts and identified that the
genes involved in the alternative bile acid synthesis pathway were expressed in the
brain compared to the classical pathway. These results were supported by targeted
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metabolomic analysis of primary and secondary bile acids measured from post-mortem
brain samples of 111 individuals. We reconstructed brain region-specific metabolic
networks using data from three independent cohorts to assess the role of bile acid
metabolism in AD pathophysiology. Our metabolic network analysis suggested that
taurine transport, bile acid synthesis and cholesterol metabolism differed in AD and
cognitively normal individuals. Using the brain transcriptional regulatory network, we
identified putative transcription factors regulating these metabolic genes and influencing
altered metabolism in AD. Intriguingly, we find bile acids from the brain metabolomics
whose synthesis cannot be explained by enzymes we find in the brain, suggesting they
may originate from an external source such as the gut microbiome. These findings
motivate further research into bile acid metabolism and transport in AD to elucidate their
possible connection to cognitive decline.
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Introduction
Alzheimer’s disease (AD), the leading cause of dementia, is a progressive, multifactorial
disease1,2 where the onset and progression of symptoms varies significantly among
individuals. Recent studies have shown that metabolic dysfunction is one of the factors
associated with neurodegenerative disorders3,4. Various physiological processes such
as lipid metabolism, immune function, amyloid precursor protein metabolism, oxidative
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stress, neurotransmitter function as well as mitochondrial functions are altered in AD
that can affect metabolism5,6,7. Interest in the transport of biochemical compounds
between the brain and the gut and their possible role in regulating metabolic changes
centrally and peripherally has increased recently across several neurodegenerative
diseases8,9. There is increasing evidence to suggest a role in AD for primary and
secondary bile acids7,10,11. Bile acids are amphipathic molecules and primary bile acids
are derived from cholesterol mostly in the liver, whereas secondary bile acids are
typically produced by bacteria in the gut12. Increased levels of secondary bile acids and
ratios to their primary bile acid educts have been linked to AD and cognitive decline7.
Cholesterol metabolism and transport have been studied extensively and are clearly
linked with AD13,1,14. Cholesterol clearance leads to production of bile acids that carry
out lipid absorption, cholesterol homeostasis and also function as signaling molecules15.
Primary bile acids such as cholic acid and chenodeoxycholic acid are synthesized as a
result of cholesterol efflux and then conjugated with glycine or taurine for secretion into
bile and later metabolized by gut bacteria12. There are two major bile acid biosynthetic
pathways: the classical pathway (neutral pathway) and the alternative pathway (acidic
pathway). The classical pathway in mammalian liver is initiated by cholesterol 7α-
hydroxylase (CYP7A1) and subsequently requires 12α-hydroxylase (CYP8B1) amongst
numerous other enzymes for synthesis of cholic acid, whereas chenodeoxycholic acid is
produced in the absence of CYP8B116. Sterol 27-hydroxylase (CYP27A1) is required for
the initiation of alternative bile acid pathway17. In the brain, sterol 24-hydroxylase
(CYP46A1) converts cholesterol to 24S-hydroxycholesterol (systematic name cholest-5-
4
en-3β,24S-diol), and subsequent 7α-hydroxylation is carried out by 24-
hydroxycholesterol 7α-hydroxylase (CYP39A1)18 (Figure 1). Studies in human and
mouse brain samples, as well as cell lines have shown that bile acids can cross the
blood-brain barrier and bind to nuclear receptors, causing physiological changes19,20.
There is limited information on the role of bile acids in the human brain and their
association with cognitive decline in AD pathophysiology. Systematic analysis of omics
data derived from blood and post-mortem brain samples of AD and cognitively normal
(CN) or control individuals has the potential to identify differences in cholesterol and bile
acid metabolism and how they contribute to AD pathogenesis. 
In this study, we analyzed a large number of transcriptome data from the Religious
Orders Study and Memory and Aging Project (ROSMAP), Mayo Clinic and the Mount
Sinai Brain Bank that had a total of 2114 post-mortem brain samples from seven
different brain regions. We reconstructed metabolic networks using the data from these
three cohorts and studied the role of circulating bile acids that may contribute to AD and
altered cholesterol metabolism in these individuals. We also generated targeted
metabolomics data of primary and secondary bile acids from post-mortem brain
samples of 111 AD patients and controls.
Various genomic studies have reported transcriptional regulatory changes in
neurodegenerative diseases21,22. The biological significance of these transcription
factors (TFs) regulating metabolic changes is not completely understood. The brain-
specific metabolic and transcriptional regulatory networks proved useful in identifying
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candidate metabolites and genes involved in the disease manifestation. A schematic
representation of the study is represented in Figure 1. Our study used the following
approaches to investigate the role of bile acids in AD:
(i) Transcriptional profiling of genes that are involved in cholesterol and bile acid
metabolism using publicly available data from post-mortem brain samples. 
(ii) Reconstruction and analysis of genome-scale metabolic networks of various
brain regions to identify genes and reactions that are significant in AD vs CN.
(iii) Transcriptional regulatory network analysis of brain samples to predict
candidate TFs regulating metabolically important genes.
In summary, our study addresses an important need to better understand potential roles
for bile acids in AD pathophysiology.
Results
In recent studies, cytotoxic and neuroprotective bile acids were identified in AD and their
probable link to cognitive decline in the individuals was reported7,23. To further
investigate the role of primary and secondary bile acids in AD and CN individuals, we
analyzed 2114 post-mortem brain samples from three independent cohorts for seven
brain regions (Table 1) and selected genes involved in cholesterol and bile acid
metabolism. 
Table 1: Details of brain region-specific samples from three different cohorts. The total
number of post-mortem brain samples for different regions, method of preparation of
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RNA-sequencing library preparation, number of samples for different pathologies,
gender and APOE status of the individuals is described in the table.
In this study, we studied the role of bile acids in AD pathology in the context of genome-
scale metabolic and transcriptional regulatory networks (Figure 1).
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Figure 1: Graphical overview of analyses described herein to study altered cholesterol 
and bile acid metabolism in AD. Numbers of samples from each brain region are 
indicated along with AD and control samples and Male/Female breakdown in 
parentheses. We used the post-mortem brain sample transcriptome data to generate 
region-specific metabolic networks. We used these networks to study bile acid and 
cholesterol metabolism. Using the brain transcriptional regulatory network, we identified 
transcription factors that regulate genes in cholesterol and bile acid metabolism.
Transcriptomic analysis of enzyme-encoding genes associated with bile acid 
metabolism
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Bile acids are products of cholesterol metabolism. To identify cholesterol and bile acid
genes that are expressed in the brain, we curated a list of regulators, transporters and
biosynthesis genes in these three independent cohorts. Cholesterol biosynthesis
regulators SREBF1 and SREBF2 were expressed in post-mortem brain samples and
recent studies have identified variants of SREBP2, the protein encoded by SREBF2,
and their probable link with AD14,24,25. Expression of genes involved in cholesterol
transport ABCA1, ABCA5, ABCA7, APOE, LPL and LCAT and members of the LDLR
gene family (LDLR, VLDLR, LRP1, LRP2, LRP4, LRP5, LRP6, LRP8, LRAD3) in the
brain samples suggests active transport of cholesterol and cholesterol homeostasis in
brain (Figure 2). ABCA7, a cholesterol transporter, belonging to the class of ATP-
binding cassette transporters that has been identified as a risk factor for late-onset of
AD17, is not found in the existing KEGG pathways and was manually curated into our
models. ABCA7 was found to be expressed in the post-mortem brain samples. We also
probed into genes encoding for receptors linked with the classical and alternative bile
acid pathway and found expression of PPARA, PPARG, LXRα/, RAR and RXRs
(RXRA, RXRB, RXRG) in the samples but no evidence of expression of FXR.
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Figure 2: Heatmap for genes involved in (a) cholesterol and (b) bile acid metabolism.
The color gradient is based on ubiquity score calculated for the genes and gray color
represents genes having no expression data on the brain regions from three cohorts.
Brain regions represented in the plot are cerebellum (CER), prefrontal cortex (FC),
temporal cortex (TC), frontal pole (FP), inferior frontal gyrus (IFG), parahippocampal
gyrus (PHG) and superior temporal gyrus (STG). The function of genes is indicated on
the left side of each heatmap.
We observed consistent expression of CYP27A1 and CYP7B1, which are involved in
the initial steps of the alternative bile acid pathway depicted in Figure 3, from the
analysis of transcriptomic data of post-mortem brain samples from three independent
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cohorts (Supplementary file 1). In the figure, the bile acids have been marked as
cytotoxic and neuroprotective7,23, but all bile acids become toxic at elevated
concentrations because of their ability to solubilize membranes23. We did not observe
expression of CYP7A1 and CYP8B1, suggesting that the classical bile acid biosynthesis
pathway is not prevalent in the brain samples. The classical pathway is known to be
most active in the liver26. It has been reported that neural cholesterol clearance through
bile acid synthesis is mediated by CYP46A1 and subsequently by CYP39A1 in the liver,
leading to synthesis of chenodeoxycholic acid27. In addition to genes involved in the
alternative bile acid pathway, we also observed expression of brain-specific CYP46A1
and CYP39A1 genes in all the cohorts. This analysis suggested that the brain utilizes an
alternative and neural cholesterol clearance pathway of bile acid synthesis27,11 and not
the classical pathway23.
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Figure 3: Schematic representation of bile acid synthesis pathway in humans. The
order of enzymatic reactions can vary. Genes expressed in brain samples from our
analysis are highlighted in pink. Based on the results from7, bile acids have been
marked as neuroprotective or cytotoxic.
Metabolomics analysis of post-mortem brain samples to identify levels of primary and 
secondary bile acids
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Bile acids were quantified from 111 post-mortem brain samples from the dorsolateral
prefrontal cortex of AD, MCI and CN individuals in the ROSMAP study
(https://www.synapse.org/#!Synapse:syn10235594) (Supplementary file 2). Although
the genes involved in production of cholic acid were not expressed in the brain samples,
detection of cholic acid from the metabolomics analysis suggested that cholic acid might
enter the brain from the periphery as previously shown in other studies20,28,29. We
compared the levels of primary and secondary bile acids in individuals with CERAD
score of 1-4, where 1, 2, 3 and 4 indicate definitive AD, probable AD, possible AD and
no evidence of AD, respectively. The ratio of primary conjugated and secondary bile
acids with respect to cholic acid (CA) showed that deoxycholic acid (DCA), lithocholic
acid (LCA), glycochenodeoxycholate (GCDCA), chenodeoxycholic acid (CDCA),
taurodeoxycholic acid (TDCA), glycodeoxycholic acid (GDCA), ursodeoxycholic acid
(UDCA), allolithocholate (alloLCA) and taurocholic acid (TCA) were higher in individuals
with AD (CERAD score 1-3) compared to controls (Figure 4). Similar results were
reported in the serum metabolomics samples of AD and CN individuals7,10. Allo-cholic
acid (ACA) is a steroid bile acid has been studied in the context of signaling
mechanisms related to differentiation, proliferation or apoptosis of hepatocytes30. The
CDCA:CA ratio was calculated and it showed a higher value for AD compared to CN
individuals in the study (Supplementary file 3). This finding suggests that the alternative
bile acid pathway is more active in AD versus CN individuals. Also, the higher ratio of
primary bile acid like TCA and secondary bile acids such as DCA, LCA, TDCA and
GDCA in AD individuals indicated that these bile acids may be associated with cognitive
function.  
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Figure 4: Bar plots representing ratio of bile acids with respect to cholic acid (primary 
bile acid) measured from 111 brain samples from ROSMAP study. Blue bars represent 
AD samples and light orange bars represent control samples.
The primary BAs are conjugated with glycine or taurine for secretion into bile17. In
addition to the primary and secondary BAs, we also measured levels of taurine in serum
samples in AD and CN individuals. In the serum, we observed that AD patients had
higher levels of serum taurine compared to controls. Taurine is required for conjugation
of primary and secondary bile acids. This is an interesting observation and we need to
explore the transport and physiological levels of taurine in the brains of individuals with
AD.
14
Metabolic reconstruction of brain regions and pathway-level analysis
We reconstructed metabolic networks for brain region-specific samples in the three
independent cohorts. The seven brain regions in this study included cerebellum (CER),
prefrontal cortex (FC), temporal cortex (TC), frontal pore (FP), inferior frontal gyrus
(IFG), parahippocampal gyrus (PHG) and superior temporal gyrus (STG). We used
transcriptome data from post-mortem brain samples for reconstructing metabolic
networks (see Methods for more details). The brain region-specific metabolic networks
consisted of ~5600-6300 reactions, 2800-4000 metabolites and each model had genes
varying from 1500-1757 in these networks. Supplementary Figure 1a provides
information of the numbers of reactions, metabolites and genes present in each of the
brain region-specific networks and Supplementary Figure 1b compares the gene
content overlaps across each of these networks. We have made the detailed content of
all of these models available to the scientific community (Supplementary file 4-10).
We tested each model using 16 brain-specific in silico tests meant to mimic
experimental evidence of metabolic functions in the brain (‘metabolic tasks’)
(Supplementary file 11), that were obtained from a recently published work on human
reconstruction31. These metabolic tasks represent a set of reactions that are brain-
specific, and the metabolic networks generated passed 65-85% of the tasks (see
Methods section). The metabolic tasks are listed in Supplementary file 11 and the
models have been provided in SBML in Supplementary file 12-18. In addition to
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generating brain region-specific metabolic networks, we also used the transcriptome
data of 2114 post-mortem brain samples and obtained personalized networks for each
sample in the study. Out of 2114 brain samples, 818 samples corresponded to
individuals with AD, 138 possible AD, 137 probable AD and 617 controls. The dataset
also consisted of 12 samples from other dementias, 163 samples with progressive
supranuclear palsy, 58 samples with pathologic aging and 2 samples that were
uncharacterized. From our metabolic networks, we identified 518 reactions that were
involved in cholesterol metabolism, bile acid synthesis and transport of bile acids
between different compartments in the metabolic networks. The personalized metabolic
networks had distinct set of bile acid reactions active in the brain regions (details in the
Methods section). Since the post-mortem brain samples for the brain regions were
collected by three independent cohorts having different sequencing protocols and
depth, the flux results were analyzed separately for these cohorts. The data suggest
that the cerebellum and temporal cortex have similar sets of bile acid reactions that can
be active in the personalized metabolic networks (Figure 5). 
16
Figure 5: Clustergram for 518 reactions involved in bile acid metabolism in (a) Mayo
clinic cohort (cerebellum and temporal cortex), (b) ROSMAP cohort (frontal cortex) and
(c) Mount Sinai Brain Bank (frontal pole, inferior temporal gyrus, superior temporal
gyrus and parahippocampal gyrus). The rows correspond to bile acid reactions in the
network and the columns are colored based on the brain regions.
We analyzed the reaction fluxes and found a similar set of bile acid reactions carrying
fluxes in metabolic networks of these independent cohorts. We used this information to
carry out statistical analysis and identify reactions that are significantly different (p-value
< 0.05) in brain regions of AD versus the CN individuals as well as identify reactions that
were significant in males versus females with AD. We found reactions carrying out
transport of taurine and cholesterol were significant in the dorsolateral prefrontal cortex,
temporal cortex and parahippocampal gyrus. Taurine is an abundant amino acid
present at roughly 1.2 mM in brain32. SLC6A6 (TAUT) and SLC36A1 (PAT1) function as
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taurine transporters and increased transport of taurine across the blood brain barrier
(BBB) has been reported for oxidative stress conditions33. We found expression of both
these genes in the brain transcriptome dataset, suggesting that these genes are
expressed in the brain and involved in transport of taurine. Table 2 provides details for
significant bile acid reactions in brain regions identified from our analysis. 
Table 2: List of bile acid reactions from our metabolic analysis of brain regions. The
reactions are represented in their VMH IDs and information related to the genes and
subsystems are also shown in the table. P-values calculated by Fisher’s exact test are












r2146 SLCO1A2 Transport, extracellular 0.023
TAUBETAtc SLC6A6 Transport, extracellular 0.009
Temporal cortex







TAUPAT1c SLC36A1 Transport, extracellular 0.0165





EBP1r EBP Cholesterol metabolism 0.0433
HMGLx HMGCL Cholesterol metabolism 0.0293
DHCR241r DHCR24 Cholesterol metabolism 0.0413
EBP2r EBP Cholesterol metabolism 0.0277
PHG





r1052   Transport, lysosomal 0.047
r2146 SLCO1A2 Transport, extracellular 0.009
RE1796R
HSD3B1, 
HSD3B2 Bile acid synthesis 0.003
TAUPAT1c SLC36A1 Transport, extracellular 0.015
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From our analysis, we identified reactions with CYP27A1, required by both the neural
cholesterol clearance pathway and the alternative bile acid pathway, as being significant
in AD versus CN brains. Other than bile acid synthesis, reactions involving metabolites
such as 7a-hydroxycholesterol (Virtual Metabolic Human (VMH, www.vmh.life, REF ID:
xol7a), 7a-hydroxy-5b-cholestan-3-one (VMH ID: xol7ah), 3a,7a-dihydroxy-5b-
cholestane (VMH ID: xol7ah2) and 7a-hydroxy-cholestene-3-one (VMH ID: xol7aone)
were also identified as being significantly different between AD and CN (p-values for
these reactions reported in Table 2). Transport of bile acids such as taurolithocholic acid
3-sulfate (VMH ID: HC02198), ursodeoxycholic acid (VMH ID: HC02194), taurocholic
acid (VMH ID: tchola) and 3-dehydroxychenodeoxy cholic acid (VMH ID: 3dhchchol)
can also be probed further to understand the role of these bile acids in AD. Thus, in
silico analysis of brain region-specific metabolic models provides insights into reactions
that may be involved in metabolic changes in AD that can be validated from
experimental data.
Identifying transcriptional regulators responsible for altered metabolism in AD
Transcription factors are one important aspect of metabolic regulation that operate
through adjusting the expression of enzyme-encoding genes. Using a transcriptional
regulatory network informed from the same Mayo temporal cortex bulk RNA-seq
samples used for the metabolic reconstruction, we identified candidate TFs that interact
with metabolic genes in cholesterol and bile acid metabolism. We selectively studied
those genes that belonged to reactions that were significantly differentially expressed in
AD versus controls, in order to study their role in AD. For example, one gene that came
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up from our metabolic analysis of AD and controls was emopamil binding protein (EBP)
(Figure 6). EBP is involved in cholesterol metabolism as it is responsible for one of the
final steps in the production of cholesterol. Our brain TRN analysis identified POU6F2,
IRF2, SMAD5, GABPA and TBR1 as the top candidate TF regulators for EBP.
Regulation by these TFs can help in understanding their role in altered cholesterol
metabolism in AD, particularly in evaluating the summation of coordinated changes
since these TFs of course control other genes as well. CYP27A1, as mentioned earlier,
is part of the alternative bile acid synthesis pathway and CREB3L2 and SOX8 are
putative TFs that regulate expression of this gene. CREB3L2 (cAMP-responsive
element binding protein 3-like 2) is induced as a result of ER stress and may function in
unfolded protein response signaling in neurons34. Other than the metabolism related
genes, we also evaluated interactions of bile acid transporters such as SLC6A6,
SLCO1A2, ABCC1, ABCA1, SLC36A1, ABCA8 and their transcriptional regulation. As
seen in Figure 6, SREBF2 was found to interact with ABCA1 and recently there were
reports of variants of SREBP2 that have been linked with AD25. Increased SREBF2
expression leads to higher cholesterol levels and presumably oxysterol and
cholestenoic acid levels which are ligands of LXR. The peroxisome proliferator-activated
receptors (PPARs) regulate various physiological processes and are expressed in the
central nervous system. PPARA regulates genes involved in fatty acid metabolism and
has been reported to regulate neuronal ADAM10 expression, in turn affecting
proteolysis of amyloid precursor protein35. PPARA was identified as a putative regulator
of ABCA1 in our brain transcriptional regulatory network. ABCA1 plays a role in
cholesterol metabolism and transport and is a candidate risk gene for late onset
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Alzheimer's disease (LOAD)36. SLC6A6, involved in transport of taurine, was found to
be putatively regulated by STAT1, a TF reported to play an important role in spatial
learning and memory formation37, and RXRG, that forms heterodimers with retinoic acid
(RA), LXRs and vitamin D receptors (VDR) 38. Neuronal differentiation 6 (NEUROD6)
functions in neuronal development, differentiation, and survival in AD39 . Regulation of
SLC36A1 by NEUROD6 indicated that this TF plays a role in controlling transport of
taurine in the brain. These interactions can be probed further to understand their role in
AD pathophysiology.
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Figure 6: Transcriptional regulatory network of brain highlighting transcription factors
and metabolic genes involved in cholesterol and bile acid metabolism. TFs are
represented as blue triangles, bile acid metabolism genes as yellow circles and
cholesterol metabolism genes as pink rectangles. The significant genes are highlighted
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with red border and transcription factors in darker shade of blue. Red edges represent
interactions between genes and TFs.
In summary, the brain transcriptional regulatory network analysis led to the identification
of candidate TFs that regulate genes in cholesterol and BA metabolism, providing clues
towards possible roles in bile acid dysregulation in AD. 
Discussion
We carried out a systematic study to identify alterations in cholesterol and bile acid
metabolism in AD versus cognitively normal (CN) controls using patient-derived post-
mortem transcriptomics and metabolomics data. The primary findings of our study are:
(1) alternative and neural cholesterol clearance pathway of bile acid synthesis pathway
genes were expressed in the brain samples included in this study, indicating that these
pathways are prevalent in the brain as compared to the classical bile acid synthesis
pathway; (2) targeted metabolomics analysis of post-mortem brain samples identified
primary and secondary bile acids and higher ratio of GCDCA:CA and secondary bile
acids like DCA, LCA, TDCA, CDCA and GDCA in AD vs controls suggests that these
bile acids might be associated with cognitive decline in AD; (3) the presence of
secondary bile acids in metabolomics data suggests a possible role of gut microbiome
in AD and highlights the need to study the gut-brain axis to understand changes in AD;
(4) transporters associated with taurine and cholesterol metabolism showed different
usage based on our genome-scale metabolic network analysis of three independent
cohorts; and (5) transcriptional regulatory network analysis identified transcription
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factors including PPARA, RXRG and SREBF2 regulating bile acid and cholesterol
genes in the brain. 
Role of bile acids in AD pathophysiology and use of genome-scale metabolic models
Bile acids are derived from cholesterol and their synthesis is regulated by complex
feedback mechanisms12,18. Recent studies have identified bile acids in brain samples
and linked them with cognitive decline in AD7,10,19. To understand the physiological role
of bile acids in the brain of AD and CN individuals, we analyzed transcriptome data from
post-mortem brain samples obtained from three independent cohorts and identified
genes involved in the alternative bile acid pathway were expressed compared to the
classical pathway in the brain. The alternative bile acid pathway is initiated by CYP27A1
that catalyzes the steroid side-chain oxidation and in the subsequent step forms C24-
bile acids. It is also known that cholesterol is converted to 24-hydroxycholesterol by
sterol 24-hydroxylase (CYP46A1) in the brain and the gene was found to be expressed
in the brain samples. The primary bile acids conjugate with glycine and taurine to form
secondary bile acids. Taurine has a neuroprotective role in the brain and bile acids
conjugated with taurine are found to be present in the brain. Metabolomics data of
serum samples showed AD patients had higher levels of serum taurine compared to
controls, indicating taurine transport across the BBB might be affected in AD. The
presence of secondary bile acids in the post-mortem brain samples suggests that these
bile acids are either endogenously present in the brain or they are transported through
the BBB. Bile acids such as ursodeoxycholic acid, taurocholic acid, taurolithocholic acid
3-sulfate and 3-dehydroxychenodeoxy cholic acid were also identified from our analysis
and the role of these bile acids can be probed further. Based on an association study,
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taurolithocholic acid was predicted to be a cytotoxic bile acid whereas chenodeoxycholic
acid and ursodeoxycholic acid were predicted as neuroprotective bile acids7. Our
analysis of transcriptome data of 2114 samples mapped into metabolic networks of
brain regions implicated reactions involved in the production of metabolites such as 7-
hydroxycholesterol, 7-hydroxy-5-cholestan-3-one, 7-hydroxycholestene-3-one and
other derivatives that are formed through CYP7A1 being significantly different (p-values
for these reactions reported in Table 2) between AD vs CN. Although CYP7A1 was not
expressed in the post-mortem brain samples, the difference in abundance of these
metabolites in AD vs CN suggests that we should explore the possibility of these
metabolites entering the brain through the periphery. In this study, we have used
transcriptomic data that was available from three independent cohorts. Transcriptomics
data is insufficient to parametrize the metabolic models, but if a denser longitudinal
omics data becomes available in the future it will help in improvising the predictions
from these in silico models. Although our analysis indicates reactions that are
significant in these conditions, the directionality of the reactions can be solidly
determined only if we have additional time-series metabolomics data (and ideally
isotopic labeling experiments) to support these changes. Methods are now being
developed to obtain cell type-specific data 40, 41), so that we can gain additional
information into the brain cells that are involved in regulating metabolic changes in AD.
These studies have shown that microglia and neuronal cells had different transcriptional
responses in AD versus control. Integrating such cell-specific data will help in refining
the models and making more accurate predictions. Our brain-tissue metabolic models
can be used by the community to capture in silico changes and possibly identify
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metabolic biomarkers prior to disease manifestation, making them useful in
understanding interactions and mechanisms between different classes of metabolites
and AD pathophysiology.
Transcriptional regulation of bile acid and cholesterol genes
Metabolism is influenced by regulation of transcription factors and metabolic genes. In
this study, we used a transcriptional regulatory network of brain (and selected brain
regions) to identify candidate TFs that may interact with genes in cholesterol and bile
acid metabolism. We identified SREBF2, PPARA, RXRG and other transcription factors,
some of which have been studied and implicated in Alzheimer’s disease. SREBF2
expression enhances cholesterol levels42 and presumably oxysterol and cholestenoic
acid levels which are ligands of LXR43. LXRs and the genes regulated by LXRs such as
ABCA1, ABCG1 and APOE, modulate intracellular cholesterol content and cholesterol
efflux and have been associated with AD pathogenesis44. Our analysis also identified
PPARA as putative regulator of ABCA1 and recent studies have demonstrated that
PPAR pathway activation increased ABCA1 levels, that in turn lead to APOE lipidation
and amyloid ß clearance45. We also identified transport of taurine as an important factor
from the metabolic analysis. SLC6A6 (neurotransmitter transporter, taurine) and
SLC36A1 (neutral amino acid/proton symporter) play a role in taurine transport.
Although there was a 1.02 to 1.3-fold change in the expression of these transporters in
AD compared with control samples of the three cohorts across four tested brain regions,
this difference was only found to be statistically significant in cerebellum
(Supplementary file 1). Integration of expression data with metabolic network of brain
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regions identified reactions involving taurine transporters that were statistically
significant in AD versus controls, further supporting their potential role. We had also
STAT1 is a putative TF of SLC6A6, identified from our analysis of brain regulatory
network. Studies have suggested that the increased STAT1 may be involved in
inflammation in AD brain37,46. NEUROD6 regulates the activity of SLC36A1, a proton-
coupled amino acid transporter. NEUROD6 is a basic helix-loop-helix TF and SNPs in
NEUROD6 have been associated with AD, especially in APOE4+ women47. Our
analysis has been able to capture metabolic genes and putative TFs that regulate them.
These findings can be further strengthened by generation of higher quality footprint data
from brain samples.
Studying the gut-brain axis to understand physiological changes in AD
Increasing evidence from experimental and clinical data suggests influence of gut-brain
axis and gut microbiota in neurodegenerative diseases48,49. From our metabolic analysis
we identified taurolithocholic, 3-dehydrochenodeoxycholic, and ursodeoxycholic acid,
secondary bile acids, significant in AD compared to CN50 suggesting a possible
connection to the gut microbiome. Recently, the bile acid deconjugation and
biotransformation pathways have been reconstructed in a resource of genome-scale
reconstructions of over 800 human gut microbes51,52. Of these, only 23 species could
synthesize 3-dehydrochenodeoxycholic acid, only four could synthesize lithocholic acid,
and only three could synthesize ursodeoxycholic acid52. For instance, the species
Ruminococcus (Blautia) gnavus, and Collinsella aerofaciens synthesize 3-
dehydroxychenodeoxycholic and ursodeoxycholic acid, and Eggerthella lenta
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synthesizes 3-dehydrochenodeoxycholic and several Clostridiales representatives
synthesize lithocholic acid52, indicating these species may play a role in Alzheimer’s
disease. Interestingly, increased lithocholic acid in plasma has recently been proposed
as a potential biomarker for Alzheimer’s disease53. Recent reports have shown
influence of bile acids to host metabolism via alterations of the bacterial community
structure54. The personalized brain models developed in this study could be joined with
personalized microbial community models established previously52,55. In future efforts,
such combined host-microbe metabolic modeling will yield more insight into
mechanisms underlying altered bile acid metabolism in Alzheimer’s disease.
STAR Methods
1. Transcriptome analysis of post-mortem brain samples
Transcriptome data was obtained from post-mortem brain samples of AD patients and
cognitively normal individuals from Religious Orders Study and Memory and Aging
Project (ROSMAP), Mayo Clinic, University of Florida, Institute for Systems Biology and
Mount Sinai Brain Bank (MSBB). 265 samples of temporal cortex (TC) and cerebellum
(CER), 632 samples of frontal cortex (FC), 303 samples of frontal pole (FP), superior
temporal gyrus (STG), inferior frontal gyrus (IFG) and parahippocampal gyrus (PHG)
with pathologies such as AD, MCI, Parkinson’s and control were analyzed and used for
construction of brain region-specific metabolic models. ROSMAP data can be requested
via the Rush Alzheimer’s Disease Center website (https://www.radc.rush.edu/). RNA-
seq libraries were prepared by different methods such as poly-A enriched, strand-
specific and ribo-zero. The RNAseq data from different centers were uniformly
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processed using a consensus set of tools with only library type-specific parameters
varying between pipelines. We have used these uniformly-processed data for analysis
in our study. Table 1 has information of number of patients with various pathologies and
controls and methods used for RNA-sequencing. The data used in the preparation of
this article were downloaded from Synapse
(https://www.synapse.org/#!Synapse:syn2580853/). We performed two-tailed t-test with
Benjamini-Hochberg correction to identify differentially expressed genes with
corresponding p-values. The differential expression analysis for transcriptome data from
three independent cohorts is presented in Supplementary file 1.
2. Bile acid sample preparation and analysis
Participants of the Religious Orders Study (ROS) are comprised of Catholic brothers,
nuns, and priests who were cognitively normal at study entry and agreed to annual
clinical examinations and brain donation at time of death. The Rush Memory and Aging
Project (MAP) is a companion study that includes community-dwelling older adults that
all agreed to evaluations similar to ROS. Quantification of bile acid concentration was
performed at the University of Hawaii cancer center. The bile acid-free matrix (BAFM)
was used to prepare bile acid calibrators. Extracts of brain tissue along with bile acid
reference standards were subjected to instrumental analysis56,57. All of the 57 bile acid
standards were obtained from Steraloids Inc. (Newport, RI) and TRC Chemicals
(Toronto, ON, Canada) and 9 stable isotope-labeled standards were obtained from
C/D/N Isotopes Inc. (Quebec, Canada) and Steraloids Inc. (Newport, RI). A Waters
ACQUITY ultra performance LC system coupled with a Waters XEVO TQ-S mass
30
spectrometer was used for all analyses. Chromatographic separations were performed
with an ACQUITY BEH C18 column. UPLC-MS raw data obtained with negative mode
were analyzed using TargetLynx™ applications manager to obtain calibration equations
and the quantitative concentration (uM) of each bile acid. Bile acids were measured
from the dorsolateral prefrontal cortex of 111 individuals with brain pathology (28, 33,
10, 22 and 18 with CERAD score of 1, 2, 3, 4 and 9 (missing), respectively).
Metabolomics data can be accessed with permission at
https://www.synapse.org/#!Synapse:syn10235594. We calculated the ratio of primary
and secondary bile acids measured in metabolomics study and performed two-tailed t-
test to calculate p-value for each bile acid.
3. Brain region-specific metabolic reconstruction
We used transcriptome data (https://www.synapse.org/#!Synapse:syn2580853/) derived
from post-mortem brain samples of three independent cohorts: Mayo clinic, ROSMAP
and Mount Sinai Brain Bank. These cohorts contained information of different brain
regions (CER, FC, TC, FP, STG, IFG and PHG) and the data was used to generate
brain region-specific metabolic networks. We converted the transcriptome data to binary
by considering transcripts with expression values less than 25th percentile in the matrix
as 0 otherwise 1. We calculated ubiquity scores for genes in each brain region
separately and used those for implementing mCADRE workflow58. The ubiquity score of
a gene is equal to the sum of samples in which the gene is expressed divided by the
total number of samples. The Recon 3D model31 of human metabolism was used as
template to reconstruct brain region-specific metabolic networks as this model had
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information of reactions related to the primary and conjugated primary acids additionally
added to refine the model. The mCADRE workflow required two inputs to build region-
specific metabolic models: (1) a global metabolic reconstruction, which in this case was
the Recon 3D model, and (2) region-specific gene expression data from many
individuals. Using the mCADRE workflow, we generated the draft reconstructions for
each brain region. We used functions in COBRA toolbox such as detectDeadEnds to
identify dead end metabolites and identifyBlockedRxns to compute all blocked reactions
in the draft reconstructions. We used reactions from the Recon 3D model for filling gaps
in the metabolic network. We carried out this step for each metabolic network
reconstructed for brain regions. We also removed the reactions belonging to drug
metabolism from the network as they were not related to functions in the brain. Only
partial urea cycle is reported to be active in the brain, and so we identified enzymes in
the urea cycle that are present in brain59 and included the reactions related to these
genes in the metabolic networks. We also included exchange reaction for metabolites
identified in the cerebrospinal fluid (CSF) (by metabolomics data as well as the whole-
body metabolism reconstruction55 and metabolites that can be taken up across the
blood brain barrier (BBB) from blood into the CSF60,61,62,63,64,65. The list of metabolites
known to pass the BBB is provided in Supplementary file 19. Using the
removeUnusedGenes function in the COBRA toolbox we removed genes that were not
used in any reaction in the reconstructions. Then we carried out manual curation for
genes present in the metabolic network using information from Human Protein Atlas66
for genes expressed in the brain. This effort helped in providing further evidence for
genes being present in the metabolic networks for brain regions. The information for
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reactions, metabolites and genes in metabolic networks of brain regions is provided in
Supplementary files 4-10. We tested our models for 16 metabolic tasks (Supplementary
file 11) that are brain specific and the models passed 65-85% of those tests. As
astrocytes are predominantly involved in maintaining brain physiology67, we used
objective function of astrocytes for our brain metabolic networks. We constrained
bounds of exchange reactions using information from a published work on metabolic
interactions between cell types in brain68. Details of metabolites involved in objective
function and bounds for constrained reactions are given in Supplementary file 4-10. We
integrated expression data with the brain region-specific metabolic networks and
generated context-specific personalized metabolic networks for each sample in the
study using iMAT algorithm69. Flux variability analysis70 was carried out to evaluate
minimum and maximum flux for each reaction in the metabolic networks. The codes
used for reconstruction and model generation and simulation are provided in GitHub
(https://github.com/PriceLab/Bile_acid_AD). We used COBRA toolbox v3.071 for
metabolic analysis that was implemented in MATLAB R2018a and academic licenses of
Gurobi optimizer v7.5 and IBM CPLEX v12.7.1 were used to solve LP and MILP
problems.
4. Reaction and pathway-level analysis
We carried out flux variability analysis70 for each context-specific personalized metabolic
network and used the values for predicting metabolic changes in AD versus CN
individuals and sex of the individuals. FVA results were used to generate a matrix in
which reactions for which both minimum (vmin) and maximum (vmax) FVA flux are 0,
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were considered to be non-active and assigned a state of 0, while the remaining
reactions were assigned a state of 1. We carried out this analysis for all context-specific
metabolic networks. Thus, our matrix contained binary values for all reactions in 2114
context-specific personalized metabolic networks for seven brain regions. We used this
scheme to classify the reactions and obtain information not only on the basis of flux
measurements but also their activity in each network. From all the reactions in the
metabolic networks, we selected only those that belonged to cholesterol metabolism,
bile acid synthesis and transport reactions associated with the bile acid metabolites. We
applied Fisher’s exact test on the binarized values of reactions to identify those
reactions with p-value < 0.05 in AD versus CN. These reactions were identified as
significant reactions in these groups.
5. Metabolic regulatory network
The transcriptional regulatory network analysis (TReNA) package
(https://rdrr.io/bioc/TReNA/) was used for identifying transcription factors (TFs) that are
part of the co-expression modules of interest. Brain-specific transcriptional regulatory
network was constructed72 using information from ENCODE. We downloaded the
DNase Hypersensitivity (DHS) fastq files from ENCODE for all available brain samples
and aligned the sequences using the SNAP method73. We performed two alignments
using seed size of 16 and 20bp. The length of sequence data was >50 bp. The regions
of open chromatin were identified using peak calling algorithm, F-Seq74. Footprints were
generated using default parameters for Wellington75 and HINT76. Our method generated
individual gene models and those footprints that are within the proximal promoter region
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(+/-5 kb of the transcription start site) are considered as priors in assessing the
relationship between the expression of the TF and target genes. We prioritized putative
TF regulators for each gene in the model using LASSO regression techniques, Pearson
and Spearman correlation and random forest methods and projected the scores from
these approaches into PCA space. The principal components were summed together to
obtain a single composite score called pcaMax. This process is part of the trena
package in Bioconductor (https://rdrr.io/bioc/TReNA/) and we applied the method to the
post-mortem samples from temporal cortex from Mayo Clinic. We used metabolic genes
identified from reaction-level analysis involved in bile acid and cholesterol metabolism
and mapped top five transcription factors that interact with these metabolic genes and
created an interaction network. This interaction networks gave information for
transcription factors that regulate metabolic genes and are involved in significant
reactions in AD versus cognitively normal individuals. Cytoscape 3.7.177 was used for
visualizing the brain transcriptional regulatory network. 
Supplemental Information
Supplementary figure 1 (a) provides information of the numbers of reactions, 
metabolites and genes present in each of the brain region-specific networks and (b) 
compares the gene content overlaps across each of these networks
Supplementary file 1: Analysis of transcriptomic data of post-mortem brain samples 
from three independent cohorts (excel file format).
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Supplementary file 2: Bile acids measurements from 111 post-mortem brain samples 
from the dorsolateral prefrontal cortex of AD, MCI and CN individuals in the ROSMAP 
study (excel file format).
Supplementary file 3: Ratio of primary and secondary bile acids with respect to cholic 
acid (excel file format)
Supplementary file 4: Details of reactions and metabolites in Cerebellum metabolic 
network (excel file format).
Supplementary file 5: Details of reactions and metabolites in Frontal cortex metabolic 
network (excel file format).
Supplementary file 6: Details of reactions and metabolites in Temporal cortex metabolic 
network (excel file format).
Supplementary file 7: Details of reactions and metabolites in Frontal pole metabolic 
network (excel file format).
Supplementary file 8: Details of reactions and metabolites in Inferior Frontal gyrus 
metabolic network (excel file format).
Supplementary file 9: Details of reactions and metabolites in Parahippocampal gyrus 
metabolic network (excel file format).
Supplementary file 10: Details of reactions and metabolites in Superior Temporal gyrus 
metabolic network (excel file format).
Supplementary file 11: Details of metabolic tasks in brain (excel file format).
Supplementary file 12: Cerebellum metabolic network (xml format).
Supplementary file 13: Frontal cortex metabolic network (xml format).
Supplementary file 14: Temporal cortex metabolic network (xml format).
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Supplementary file 16: Inferior Frontal gyrus metabolic network (xml format).
Supplementary file 17: Parahippocampal gyrus metabolic network (xml format).
Supplementary file 18: Superior Temporal gyrus metabolic network (xml format).





The code used for reconstruction and model generation and simulation are provided in 
GitHub (https://github.com/PriceLab/Bile_acid_AD)
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